Hwa-In Kim

CONTACT

Lead Sponsor

CHA University

Collaborators

Age

20 - 90 years

Sex

ALL

Healthy Volunteers

No

•Participants with positive troponin acute coronary syndrome who have undergone implantation of ultrathin bioresorbable polymer sirolimus-eluting stents (Orsiro; Biotronik AG).
•Participants who have provided written informed consent.

•Under 19 years of age.
•Stent treatment failure lesions (stent restenosis or thrombosis).
•Cardiac arrest or cardiogenic shock.
•Currently taking or requiring strong CYP3A4 inhibitors (atazanavir, clarithromycin, darunavir/ritonavir, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, tipranavir/ritonavir) or P-glycoprotein inhibitors (cyclosporine, ranolazine).
•Presence of any of the following concomitant conditions: myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia, severe gastrointestinal diseases, or genetic disorders such as galactose intolerance.
•Hypersensitivity to colchicine treatment.
•Currently taking colchicine for another condition.
•Requiring anticoagulant therapy.
•Liver disease classified as Child-Pugh class B or C.
•Renal disease with creatinine clearance \<30 mL/min.
•Pregnant, breastfeeding, or women of childbearing age.
•Currently has a malignancy or has a history of malignancy within the past 5 years.
•Life expectancy of less than 5 years.
•Contraindication for ticagrelor use (history of intracranial hemorrhage, active pathological bleeding, or liver disease classified as Child-Pugh class B or C).
•Patients receiving regular administration of systemic steroids, immunosuppressants, or biological agents (e.g., TNF-alpha inhibitors)
•Patients with active infectious diseases